Encorafenib-13C, d3

Encorafenib-13C, d3 is the 13C- and deuterium labeled Encorafenib. Encorafenib (LGX818) is a highly potent BRAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAFV600E (EC50=4 nM) .

Product Specifications

Product Name Alternative

LGX818-13C, d3

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Isotope-Labeled Compounds; Raf

Type

Isotope-Labeled Compounds

Related Pathways

MAPK/ERK Pathway; Others

Field of Research

Cancer

Purity

98.14

Solubility

10 mM in DMSO

Smiles

O=C(OC)N[C@@H](C)CNC1=NC=CC(C2=CN(C(C)C)N=C2C3=CC(Cl)=CC(NS(=O)([13C]([2H])([2H])[2H])=O)=C3F)=N1

Molecular Formula

C21 13CH24D3ClFN7O4S

Molecular Weight

544.02

Precautions

H302, H315, H319, H335

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Compounds and compositions as protein kinase inhibitors . Patent WO 2011025927 A1|[3]Li Z, et al. Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells. Cancer Lett. 2016 Jan 28;370 (2) :332-44.